Medical policies offer guidance on determination of medical necessity and appropriateness of care for approved benefits. Benefit determinations and coverage decisions are subject to all the terms and conditions of Humana – CareSource® including eligibility, definitions, specific inclusions or exclusions, and applicable state or federal laws.
The medical policies do not constitute medical advice or medical care. Treating health care providers are solely responsible for diagnosis, treatment and medical advice. Humana – CareSource is not responsible for, does not provide, and does not represent itself as a provider of medical care.
Policies are considered guidelines and are not intended to infer benefits or coverage for a specific member. Benefit determinations are based on the specific facts of each member’s case. If a service or supply is not eligible for coverage, a member and the treating provider may proceed with that service or supply after receiving a denial from Humana – CareSource for the requested non-covered service.
Existing clinical policies are regularly reviewed and updated. New policies are added as appropriate while previous versions are maintained in the policy archive. These policy changes are maintained on this site.
The policies below are in PDF format. If you do not have Adobe Acrobat Reader, you may download it here.
Current Medical Policies
|Alpha Hydroxyprogesterone Caproate (Makena)|
|Acute In-Patient Detoxification (Opioid) Prior Authorization Criteria|
|Alpha 1-Proteinase Inhibitor Injection|
|Applied Behavior Analysis (ABA) Therapy|
|Autoimmune Diseases Biologic Therapies|
|Biologic Cholesterol Agents|
|Biologic and other Ophthalmologic Agents|
|Botulinum Toxin Injection|
|Calcium Regulators (Reclast, Zometa, Boniva, Prolia, Forteo, Xgeva)|
|Colony Stimulating Factors|
|Cytomegalovirus Immune Globulin Intravenous (Cytogam)|
|Dispense as Written (DAW) Requests|
|Enzyme Replacement Therapy and Agents: Aldurazyme, Cerezyme, Eleprase, Vpriv, Fabrazyme, Lumizyme/Myozyme, Naglazyme, Elelyso, Zavesca, Cerdelga, Vimizim|
|Hematopoietic Growth Factor (Epoetin alfa, Darbenpoetin alfa, Tbo-filgrastim, Pegfilgrastim, Filgrastim and Sargramostim)|
|Hepatitis C - Oral|
|Hereditary Angioedema and Pharmacotherapy|
|Home Infusion Therapy|
|Hyaluronic Acid Derivative Injection|
|Idiopathic Pulmonary Fibrosis: Esbriet (Pirfenidone), OFEV (Nintedanib)|
|Immune (Idiopathic) Thrombocytopenia Purpura (ITP)|
|Immune Globulin (Gammaked, Carimune, Carimune NF, Flebogamma, Flebogamma DIF, Gamastan S/D, Gammagard Liquid, Gammagard S/D Less IgA, Gammaplex, Gamunex, Hizentra, Octagam, Polygam, Privigen)|
|Inflammatory Bowel Disease: Biological Therapies|
|Insulin Infusion Pump Therapy for Diabetes|
|Medication Assisted Therapy (MAT): Suboxone|
|Multiple Sclerosis Therapy Class|
|Omalizumab (Xolair) – Xolair/Nucala|
|Pegylated and Non-Pegylated Interfeon (alfa-2a Pegasys, alfa-2b Pegintron, Interferon alfa-2b Intron A)|
|Psoriasis: Biological Therapies|
|Pulmonary Arterial Hypertension|
|Seizure Disorders (Repository Corticotropin Injection (H.P. Acthar Gel) and Vigabatrin (Sabril) Oral Solution and Tablets)|
|Serum Biomarker Panel Testing in Systemic Lupus Erythematosus and Rheumatoid Arthritis|
|Short Bowel Syndrome Policy (Gattex, Zorbitive|